LifeStance Health Group annual stock-based compensation
2019
2021
2022
2023
2024
2025
LifeStance Health Group Stock-Based Compensation Growth & History (LFST)
LifeStance Health Group's stock-based compensation was $74.7M for fiscal 2025.
View full LifeStance Health Group company overviewLifeStance Health Group annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $74.7M | −$1.5M | −1.93% |
| 2024 | 2024-12-31 | $76.2M | −$23.2M | −23.36% |
| 2023 | 2023-12-31 | $99.4M | −$88.0M | −46.97% |
| 2022 | 2022-12-31 | $187.4M | −$72.0M | −27.76% |
| 2021 | 2021-12-31 | $259.4M | — | — |
| 2019 | 2019-12-31 | $54,000 | — | — |
LifeStance Health Group quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.7M | −$1.4M | −6.48% |
| Q1 2026 | 2026-03-31 | $15.2M | −$3.4M | −18.20% |
| Q4 2025 | 2025-12-31 | $16.7M | $558,000 | +3.46% |
| Q3 2025 | 2025-09-30 | $18.3M | $3.4M | +22.84% |
| Q2 2025 | 2025-06-30 | $21.1M | −$3.4M | −13.99% |
| Q1 2025 | 2025-03-31 | $18.6M | −$2.0M | −9.70% |
| Q4 2024 | 2024-12-31 | $16.1M | −$4.8M | −22.82% |
| Q3 2024 | 2024-09-30 | $14.9M | −$6.6M | −30.80% |
| Q2 2024 | 2024-06-30 | $24.6M | −$8.5M | −25.78% |
| Q1 2024 | 2024-03-31 | $20.6M | −$3.3M | −13.76% |
| Q4 2023 | 2023-12-31 | $20.9M | −$14.3M | −40.56% |
| Q3 2023 | 2023-09-30 | $21.5M | −$13.3M | −38.27% |
| Q2 2023 | 2023-06-30 | $33.1M | −$24.4M | −42.48% |
| Q1 2023 | 2023-03-31 | $23.9M | −$36.0M | −60.13% |
| Q4 2022 | 2022-12-31 | $35.2M | −$73.4M | −67.60% |
| Q3 2022 | 2022-09-30 | $34.9M | −$85.8M | −71.11% |
| Q2 2022 | 2022-06-30 | $57.5M | $28.0M | +94.85% |
| Q1 2022 | 2022-03-31 | $59.9M | $59.3M | +9793.39% |
| Q4 2021 | 2021-12-31 | $108.6M | — | — |
| Q3 2021 | 2021-09-30 | $120.7M | $120.1M | +20962.65% |
| Q2 2021 | 2021-06-30 | $29.5M | $29.2M | +10007.88% |
| Q1 2021 | 2021-03-31 | $605,000 | — | — |
| Q3 2020 | 2020-09-30 | $573,000 | — | — |
| Q2 2020 | 2020-06-30 | $292,000 | — | — |
LifeStance Health Group stock-based compensation trends
Between the periods ended 2019-12-31 and 2025-12-31, LifeStance Health Group's stock-based compensation increased from $54,000 to $74.7M, a change of $74.6M. The latest reported quarter, Q2 2026, shows $19.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LifeStance Health Group source filings ↗